GALAPAGOS NV

GLPGF | News | $35.5157 71.75% 4.8K

(0.0% 1d) (0.0% 1m) (-6.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (240500.0% volume)
Earnings Calendar:
Market Cap: $ 2,274,107,918
http://www.glpg.com
Sec Filling | Patents | n/a employees

(BE) Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research & Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

antibody 3d

add to watch list Paper trade email alert is off

MorphoSys AG

MPSYF | News | $70.28 -71.33% 110

Health Technology

(0.0% 1d) (0.0% 1m) (154.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (223918.67% volume)
Earnings Calendar:
Market Cap: $ 2,583,142,384
http://www.morphosys.de
Sec Filling | Patents | n/a employees

(DE) MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. It operates through the Proprietary Development and Partnered Discovery segments. The Proprietary Development segment combines proprietary research and development of therapeutic compounds. The Partnered Discovery segment offers technologies to make human antibody-based therapeutics on behalf of partners in the pharmaceutical industry. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.

diagnostics antibody

add to watch list Paper trade email alert is off

Anavex Life Sciences Corp.

AVXL | News | $3.8 0.0% 2.1M

Health Technology

(0.0% 1d) (-26.0% 1m) (-52.9% 1y) (-7.1% 2d) (-7.1% 3d) (-10.6% 7d) (Infinity% volume)
Earnings Calendar: 2024-02-06
Market Cap: $ 312,027,542
http://www.anavex.com
Sec Filling | Patents | 16 employees

(US) Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

neurodegenerative alzheimer nervous system parkinson treatment alzheimer’s

add to watch list Paper trade email alert is off

Alibaba Group Holding Ltd

BABAF | News | $8.76 2.05% 6.5K

Retail Trade

(0.0% 1d) (-6.9% 1m) (-22.0% 1y) (0.0% 2d) (0.0% 3d) (-0.6% 7d) (-89.17% volume)
Earnings Calendar:
Market Cap: $ 176,729,012,501
http://www.alibabagroup.com
Sec Filling | Patents | n/a employees

(CN) Alibaba Group Holding Ltd. engages in providing online and mobile marketplaces in retail and wholesale trade. It operates through the following business segments: Core Commerce; Cloud Computing; Digital Media and Entertainment; and Innovation Initiatives and Others. The Core Commerce segment comprises of platforms operating in retail and wholesale. The Cloud Computing segment consists of Alibaba Cloud, which offers elastic computing, database, storage and content delivery network, large scale computing, security, management and application, big data analytics, a machine learning platform, and other services provide for enterprises of different sizes across various industries. The Digital Media and Entertainment segment relates to the Youko Tudou and UC Browser business. The Innovation Initiatives and Others segment includes businesses such as AutoNavi, DingTalk, Tmall Genie, and others. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

computational security machine learning

add to watch list Paper trade email alert is off

Cisco Systems, Inc.

CSCO | $48.33 0.46% 0.46% 20M

Technology Services

(0.0% 1d) (-3.1% 1m) (2.7% 1y) (0.2% 2d) (0.9% 3d) (0.2% 7d) (Infinity% volume)
Earnings Calendar: 2023-11-15
Market Cap: $ 195,697,211,576
http://www.cisco.com
Sec Filling | Patents | 77500 employees

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its product comprises of the following categories: Switches, Routers, Wireless, Network Management Interfaces and Modules, Optical Networking, Access Points, Outdoor and Industrial Access Points, Next-Generation Firewalls, Advanced Malware Protection, VPN Security Clients, Email, and Web Security. The company was founded by Sandra Lerner and Leonard Bosack on December 10, 1984 and is headquartered in San Jose, CA.

security optical information technology communication

add to watch list Paper trade email alert is off

Huntington Bancshares Incorporated

HBAN | News F | $13.29 0.84% 0.83% 40M

Finance

(0.0% 1d) (-2.4% 1m) (16.1% 1y) (0.0% 2d) (1.0% 3d) (0.2% 7d) (138.65% volume)
Earnings Calendar: 2024-01-19
Market Cap: $ 19,270,500,000
http://www.huntington.com
Sec Filling | Patents | n/a employees

Huntington Bancshares, Inc. operates as a bank holding company. It provides commercial and consumer banking services, mortgage banking services, automobile financing, recreational vehicle and marine financing, equipment leasing, investment management, trust services, brokerage services, insurance programs, and other financial products and services. The company operates through the following segments: Consumer & Business Banking, Commercial Banking, Commercial Real Estate & Vehicle Finance, Regional Banking & The Huntington Private Client Group, and Home Lending. The Consumer & Business Banking segment provides financial products and services to consumer and small business customers including but not limited to checking accounts, savings accounts, money market accounts, certificates of deposit, investments, consumer loans, credit cards and small business loans. The Commercial Banking segment provides products and services to the middle market, large corporate, and government public sector customers located primarily within its geographic footprint. The segment is divided into following business units: Middle Market, Large Corporate, Specialty Banking, Asset Finance, Capital Markets, Treasury Management, and Insurance. The Commercial Real Estate & Vehicle Finance segment provides products and services include providing financing for land, buildings, and other commercial real estate owned or constructed by real estate developers, automobile dealerships, or other customers with real estate project financing needs, and financing for the purchase of automobiles, light-duty trucks, recreational vehicles and marine craft at franchised dealerships, financing the acquisition of new and used vehicle inventory of franchised automotive dealerships. The Regional Banking and The Huntington Private Client Group segment consists of private banking, wealth & investment management, and retirement plan services. The Home Lending segment originates and services consumer loans and mortgages for customers who are located in primary banking markets. Huntington Bancshares was founded in 1966 and is headquartered in Columbus, OH.

acquisitions vehicles insurance automobile marine automotive msa construction

add to watch list Paper trade email alert is off

MorphoSys AG

MOR | News | $17.96 -0.5% -0.5% 180K

Health Technology

(0.0% 1d) (-0.3% 1m) (237.3% 1y) (-0.4% 2d) (-0.3% 3d) (-0.2% 7d) (-69.43% volume)
Earnings Calendar:
Market Cap: $ 2,705,145,042
http://www.morphosys.de
Sec Filling | Patents | 426 employees

MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. It operates through the Proprietary Development and Partnered Discovery segments. The Proprietary Development segment combines proprietary research and development of therapeutic compounds. The Partnered Discovery segment offers technologies to make human antibody-based therapeutics on behalf of partners in the pharmaceutical industry. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.

antibody diagnostics brain amyloid alzheimer gantenerumab igg1 antibody

add to watch list Paper trade email alert is off

Rallybio Corp

RLYB | News | $1.75 4.79% 4.57% 310K

(0.0% 1d) (7.3% 1m) (-62.3% 1y) (2.9% 2d) (2.3% 3d) (-3.8% 7d) (Infinity% volume)
Earnings Calendar: 2024-03-04
Market Cap: $ 66,170,948
https://rallybio.com
Sec Filling | Patents | 2021 employees

Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health and metabolic disorders. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut.

urea metabolic

add to watch list Paper trade email alert is off

KONINKLIJKE PHILIPS NV

RYLPF | News | $20.515 3.85% 7K

Health Technology

(0.0% 1d) (3.0% 1m) (-5.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (4418.83% volume)
Earnings Calendar:
Market Cap: $ 18,644,860,868
http://www.philips.com
Sec Filling | Patents | n/a employees

(NL) Royal Philips NV is a technology company, which engages in the healthcare, lighting, and consumer well-being markets. It operates through the following segments: Personal Health, Diagnosis & Treatment, Connected Care & Health Informatics, and Other. The Personal Health segment focuses on healthy living and preventative care. This segment comprises the Personal Care, Domestic Appliances, Oral Healthcare, and Mother & Child Care businesses. The Diagnosis & Treatment segment unites the businesses related to the promise of precision diagnosis and disease pathway selection, and the businesses related to image-guided, minimally invasive treatments. This segment comprises the Diagnostic Imaging, Ultrasound, Healthcare Informatics and Image-Guided Therapy businesses. The Connected Care & Health Informatics segment focuses on patient care solutions, advanced analytics and patient and workflow optimization inside and outside the hospital, and aims to unlock synergies from integrating and optimizing patient care pathways and leveraging provider-payer-patient business models. This segment comprises the Monitoring & Analytics, Therapeutic Care, Population Health Management, and Sleep & Respiratory Care businesses. The Other segment reports on the items Innovation & Strategy, IP Royalties, Central costs, and other small items. The company was founded by Anton Frederik Philips and Gerard Leonard Frederik Philips in 1891 and is headquartered in Amsterdam, the Netherlands.

diagnostics respiratory treatment optical

add to watch list Paper trade email alert is off

XOMA Corporation

XOMA | News | $24.97 1.55% 1.52% 17K

Health Technology

(0.0% 1d) (3.9% 1m) (37.1% 1y) (5.1% 2d) (5.1% 3d) (4.7% 7d) (Infinity% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 290,526,325
http://www.xoma.com
Sec Filling | Patents | 10 employees

(US) XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.

antibody

add to watch list Paper trade email alert is off